---
title: "Biohaven fell 20% after hours as its BHV-700 therapy for MDD (Major Depressive Disorder) failed to m"
description: "Biohaven fell 20% after hours as its BHV-700 therapy for MDD (Major Depressive Disorder) failed to meet primary endpoints"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270746105.md"
published_at: "2025-12-24T18:05:49.000Z"
---

# Biohaven fell 20% after hours as its BHV-700 therapy for MDD (Major Depressive Disorder) failed to m

> Biohaven fell 20% after hours as its BHV-700 therapy for MDD (Major Depressive Disorder) failed to meet primary endpoints

Biohaven fell 20% after hours, as the research results for its BHV-700 therapy targeting MDD (Major Depressive Disorder) failed to meet the primary endpoint

### Related Stocks

- [BHVN.US - Biohaven Pharmaceutical](https://longbridge.com/en/quote/BHVN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biohaven 在新的投资者演示中重点介绍了降解剂平台 | Biohaven Ltd. (BHVN) 宣布将于 2026 年 1 月 12 日举行投资者演示，详细介绍其药物开发平台的进展，特别是其 MoDE 和 TRAP 降解技术。演示强调了 BHV-1400 在 IgA 肾病和 BHV-1300  | [Link](https://longbridge.com/en/news/272300228.md) |
| Biogen｜10-K：2025 财年营收 98.91 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275127544.md) |
| 中国给予 Biogen 和 Eisai 的皮下注射 LEQEMBI 申请优先审查 | Biogen Inc. 和 Eisai Co., Ltd. 已获得中国国家药品监督管理局对其 LEQEMBI®（lecanemab）皮下给药制剂生物制品许可申请的优先审评资格。该资格旨在加快药物的评估和潜在上市，这将提供一种每周一次的居家给 | [Link](https://longbridge.com/en/news/275253143.md) |
| Biogen：有限的短期增长和执行风险使得中性持有评级是合理的 | 摩根士丹利分析师 Terence Flynn 维持了对 Biogen 的持有评级，目标价为 190.00 美元，理由是短期增长有限和执行风险。管理层的 2026 年指引显示收入将小幅下降，核心产品销售预计将收缩。尽管新产品发布和关键事件可能 | [Link](https://longbridge.com/en/news/275233131.md) |
| Anixa Biosciences 的 CEO 称 2026 年为 “关键之年”，因为乳腺癌疫苗和卵巢癌 CAR-T 疗法的推进 | Anixa Biosciences 首席执行官 Amit Kumar 博士宣布，2026 年将是公司一个关键的年份，因为它正在推进乳腺癌疫苗和卵巢癌 CAR-T 疗法。关键里程碑包括完成疫苗的第一阶段临床试验，并为第二阶段做准备。公司目前拥 | [Link](https://longbridge.com/en/news/275508535.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.